1. Barraclough, D. R. (2002). Considerations for the safe prescribing and use of COX-2-specific inhibitors. Medical Journal of Australia, 176(7), 328–331.
2. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine, 343(21), 1520–1530.
3. CNT. (2013). Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet, 382(9894), 769–779. doi:10.1016/S0140-6736(1013)60900-60909.
4. Day, R. O., & Graham, G. G. (2013). Non-steroidal anti-inflammatory drugs (NSAIDs). British Medical Journal (Clinical research ed.). 346 , 2013. Article Number: f3195.
5. Donath, M. Y., & Sheldon, S. E. (2011). Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology, 11(2), 98–107.